144 ·Filed Jun 9, 2026

HRMY

Harmony Biosciences Holdings, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago SEC0001950047-26-005832
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

The proposed sale is small (0.05% of market cap) and by a former officer, not current management. No material negative read-through. Monitor for actual Form 4 filings to confirm execution, but this filing alone does not signal distress or deteriorating fundamentals.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+20d
HRMY ▲ +7.69% at T+20d
NEUTRAL call ✓ call won +7.69% · α vs SPY +4.07% · entry $35.48 → $38.21
Next anchor: T+60d due 29d ago
Latest observation: T+58 +9.43% FF3 residual α
Entry anchored
Jun 9, 03:59 PM ET
via exchange tick
T+1d
-0.79%
call -0.79% · α -2.49%
$35.20
settled 4mo ago
T+5d
-4.65%
call -4.65% · α -8.08%
$33.83
settled 4mo ago
T+20d
+7.69%
call +7.69% · α +4.07%
$38.21
settled 3mo ago
T+60d
—
call — · α —
—
due 29d ago

Price Chart

Loading chart...

Executive Summary

Former officer Sandip Kapadia filed a Form 144 notice of intent to sell up to 27,960 shares (~$943K at recent prices), acquired via cash exercise of options. The sale is routine and proportional relative to the $1.9B market cap, representing a small fraction of typical insider holdings.

Key Facts

  • Sandip Kapadia (former officer) intends to sell 27,960 shares of HRMY common stock.
  • Approximate value ~$943,264 based on filing.
  • Shares acquired via exercise of options under a registered plan on June 5, 2026.
  • Sale intended for June 9, 2026 on Nasdaq.
  • This is intent to sell, not a completed sale.
  • Three prior sales by same insider on 6/4/2026 (7,064 sh), 6/5/2026 (2,101 sh), and 5/8/2026 (45,481 sh) are noted in the filing.

Financial Impact

Up to $943K in potential insider selling, representing ~0.05% of the $1.9B market cap.

dilutioninsider selling

Risk Factors

  • Insider selling could marginally pressure the stock if executed quickly.
  • Former officer selling post-option exercise is routine, but any acceleration beyond this filing would be a concern.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
65% bullish (17 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005832
Document: 0001950047-26-005832-index.html0001950047-26-005832
Document: 0001950047-26-005832.txt0001950047-26-005832
12 reports for HRMY
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+20▲ +14.82%Jul 16, 2026
Filters
Rows
Reports for HRMY — sortable, filterable
TypeNow
Aug 4, 2026
8w ago
8-K
BULLISH ★ 7/10
$38.78 $39.52▲ +1.91%▲ +2.01%$40.53 (+4.53%)
Aug 4, 2026
8w ago
Press Release
BULLISH ★ 6/10
$38.78 $39.52▲ +1.91%▲ +2.01%$40.53 (+4.53%)
Jul 16, 2026
11w ago
8-K
BULLISH ★ 7/10
$33.53 $35.80▲ +6.77%▲ +8.44%$40.53 (+20.89%)
Jun 30, 2026
13w ago
144
BEARISH ★ 5/10
$36.00 $38.26▼ −6.28%▼ −6.02%$40.53 (−12.60%)
Jun 24, 2026
14w ago
144
BEARISH ★ 5/10
$34.13 $36.00▼ −5.48%▼ −3.92%$40.53 (−18.77%)
Jun 9, 2026
16w ago
144
NEUTRAL ★ 3/10
$35.48 $33.83▼ −4.65%▼ −8.08%$40.53 (+14.25%)
Jun 5, 2026
16w ago
144
NEUTRAL ★ 3/10
$32.39 $34.18▲ +5.53%▲ +3.41%$40.53 (+25.15%)
May 19, 2026
19w ago
3
NEUTRAL ★ 5/10
$30.44 $30.76▲ +1.05%▼ −1.25%$40.53 (+33.16%)
May 7, 2026
21w ago
8-K
MIXED ★ 5/10
$31.42 $30.83▼ −1.88%▼ −3.38%$40.53 (+29.01%)
Apr 14, 2026
24w ago
8-K
MIXED ★ 6/10
$29.29 $32.14▲ +9.73%▲ +8.34%$40.53 (+38.39%)
Showing 10 of 12

US Market Status

Market Open — Closes in 5h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access